LY-3435151

N/A

Report date: 2023/12/18 18:08:57

Base Information

Drug NameLY-3435151
Drug Alias NameLY-3435151
ClassificationBiologics
Mechanisms of ActionCD226 antigen blockers
TargetsCD226 antigen
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsOvarian Neoplasms +[10
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursUterine Cervical NeoplasmsOvarian Neoplasms +[10

Other Information

ATC CodeN/A
Related LinksN/A